drugset / Trial / NCT02341482

A Study to Evaluate the Effect of Itraconazole on the Pharmacokinetics of PF-04958242 in Healthy Subjects

NCT02341482

Phase 1 Completed 13 enrolled Biogen
Non-randomizedSingle-groupOpen-labelTreatment

Summary

The purpose of the current study is to characterize the pharmacokinetic (PK) profile of PF 04958242 when co administered with a strong cytochrome P450 3A4 (CYP3A4) inhibitor.

Timeline

Start
2015-02-05
Primary completion
2015-03-31
Completion
2015-03-31

Drugs

EvaluationDrugModalityDoseRoute
Subject PESAMPATOR Small molecule 0.025 mg
Background Itraconazole Small molecule 200 mg

Indications

No indication recorded.